| |
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-Term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs
|
| |
| |
This study is currently recruiting patients.
NOTE: At the current time the use of TMC-125 is not permitted if enrolled in the MK-0518 Merck Integrase inhibitor EAP. This may change.
The primary objective of TMC125-C214 is to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs.
The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected.
The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens. Information on safety and tolerability aspects of TMC125 in combination with other ARVs in treatment-experienced HIV-1 patients with limited treatment options will be assessed. Available data regarding the effectiveness of the drug will also be collected. To be eligible, patients should be failing their current ARV regimen or be on a treatment interruption, should have previously received 2 different protease inhibitor (PI) containing regimens and be at least 3-class experienced (protease inhibitors [PI], nucleoside/tide reverse transcriptase inhibitors [N[t]RTIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) or at least 2-class experienced (PIs and N[t]RTIs) with primary NNRTI resistance. TMC125 will be administered in combination with an investigator-selected background of additional ARVs from the list of allowed medications.
This is an open label trial with primary objective to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected. Patients should be at least 3-class experienced or 2-class experienced with primary non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. They should also have previously received 2 different protease inhibitor-based regimens (low-dose ritonavir is not counted as a protease inhibitor (PI) regimen), be on a treatment interruption or not be virologically suppressed on their current regimen, and not be able to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance. Patients must also meet all in- and exclusion criteria. TMC125 (200mg twice daily) will be provided once the patient has been confirmed eligible for entry. Once treatment with TMC125 in combination with other ARVs has been initiated, patients must be instructed to follow the recommended visit schedule based on routine clinical care. Safety and tolerability of the entire antiretroviral therapy (ART) regimen, including TMC125, should be monitored by the investigator as per standard clinical practice. However, it is recommended that visits be planned 4 and 12 weeks following initiation of TMC125 in combination with other ARVs and every 12 weeks thereafter while on therapy during this trial. Adverse events (AEs) leading to treatment interruption or discontinuation and all serious adverse events (SAEs), with the exception of Acquired Immunodefiency Syndrome (AIDS) defining illnesses (CDC class C) unless fatal or considered to be related to TMC125, will be collected. Other adverse events will be collected only if required as per local regulations. The background ARVs may be changed at any time during the trial, at the discretion of the investigator due to the development of resistance, intolerance, toxicity, etc. while continuing treatment with TMC125 if in the investigator's assessment the patient still benefits from treatment with TMC125. If changes in the background regimen are made, it is recommended that a follow-up visit be planned 4 weeks after the change in therapy. Treatment with investigational medication will be continued until virologic failure, treatment-limiting toxicity, subject lost to follow-up, patient's withdrawal, pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country.
Patients will be instructed to orally take two 100 mg tablets of TMC125 following a meal every 12 hours. TMC125 (200 mg twice daily) must be used in combination with other antiretroviral drugs. Treatment with investigational medication will continue until virologic failure, treatment-limiting toxicity, patient lost to follow-up, withdrawal, pregnancy, discontiuation of TMC125 development or when TMC125 becomes commercially available in the patient's country.
Inclusion Criteria:
* Patient is at least 3-class experienced (3 classes of licensed oral antiretrovirals: nucleoside/tide reverse transcriptase inhibitors [N[t]RTI], protease inhibitors [PI], non-nucleoside reverse transcriptase inhibitors [NNRTI])
* Patients with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria
* Patient has previously received 2 different PI-based regimens
* Patient is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance
* Patient, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen
Exclusion Criteria:
* Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216)
* Use of disallowed concomitant therapy, including disallowed antiretrovirals (ARV)
* Use of investigational ARVs (with exceptions)
* Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the Screening Phase
* Pregnant or breast-feeding female
* Female patient of childbearing potential not using effective non-hormonal birth control methods
* Patients with specific laboratory abnormalities
* Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00354627
Alabama
Hobson City, Alabama, 36201, United States; Not yet recruiting
California
Willard L. Maletz, Md Inc., Long Beach, California, 90807, United States; Recruiting
Williard Maletz 562-989-6847
Willard Maletz, Principal Investigator
Connecticut
Norwich, Connecticut, 06360, United States; Not yet recruiting
Florida
Infectious Diseases Associates, Sarasota, Florida, 34239, United States; Not yet recruiting
Pat Carr 941-366-0776
Vilma Vega, Principal Investigator
Wohlfeiler, Piperato & Associates LLC, N. Miami Beach, Florida, 33169, United States; Not yet recruiting
Jaime Lopez 305-944-2884
Michael Wohlfeiler, Principal Investigator
Georgia
Family Healthcare of Atlanta, P.C., Atlanta, Georgia, 30318, United States; Not yet recruiting
Sharon Fragale 404-355-2000
Mark Tanner, Principal Investigator
Illinois
Chicago, Illinois, 60610, United States; Not yet recruiting
Chicagho, Illinois, 60657, United States; Not yet recruiting
Kentucky
Henderson, Kentucky, 42420, United States; Not yet recruiting
Missouri
Southampton Healthcare, Inc., St. Louis, Missouri, 63139, United States; Recruiting
Michael McGovern 314-647-2200
David Prelutsky, Principal Investigator
New Jersey
Garden State Infectious Diseases, Voorhees, New Jersey, 08043, United States; Recruiting
Dawn Slowinski 856-566-3190
David Condoluci, Principal Investigator
Newark, New Jersey, 07103, United States; Not yet recruiting
New York
New York Hospital Queens - Cardiac Cath Lab 3RD Floor, Flushing, New York, 11355, United States; Not yet recruiting
Susan Kiernan 718-670-2530
Sorana Segal-Maurer, Principal Investigator
New York, New York, 10011, United States; Not yet recruiting
Oregon
Portland, Oregon, 97227, United States; Not yet recruiting
Texas
David Powell Clinic, Austin, Texas, 78751, United States; Recruiting
Rhonda Ray 512-972-4901
KATHERINE BROWN, Principal Investigator
Therapeutic Concepts, Houston, Texas, 77004, United States; Not yet recruiting
Kenneth Degazon 713-526-9821
Joseph Gathe, Principal Investigator
|
|
| |
| |
|
|
|
